Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196

Watchlist Manager
Shanghai Fosun Pharmaceutical Group Co Ltd Logo
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Watchlist
Price: 26.24 CNY -3.78% Market Closed
Market Cap: 67.1B CNY
Have any thoughts about
Shanghai Fosun Pharmaceutical Group Co Ltd?
Write Note

Shanghai Fosun Pharmaceutical Group Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai Fosun Pharmaceutical Group Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Cash from Operating Activities
ÂĄ3.5B
CAGR 3-Years
8%
CAGR 5-Years
2%
CAGR 10-Years
12%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
ÂĄ3.1B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Operating Activities
ÂĄ1.2B
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
ÂĄ7.9B
CAGR 3-Years
39%
CAGR 5-Years
19%
CAGR 10-Years
18%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
ÂĄ4.5B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Operating Activities
-ÂĄ615.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai Fosun Pharmaceutical Group Co Ltd
Glance View

Market Cap
70.1B CNY
Industry
Pharmaceuticals

Shanghai Fosun Pharmaceutical Group Co., Ltd. is a leading player in the global healthcare landscape, anchored in its commitment to innovation and quality. Founded in 1994 and based in Shanghai, China, the company operates through a diverse portfolio that includes pharmaceuticals, biotechnology, medical devices, and healthcare services. With a strategic focus on research and development, Fosun Pharma has developed a strong pipeline of proprietary drugs and vaccines, enhancing its position in both domestic and international markets. Its ability to capitalize on China’s booming healthcare sector, alongside strategic alliances with reputable global firms, positions it as a formidable competitor in the ever-evolving landscape of healthcare. For investors, Fosun Pharma presents an intriguing opportunity, characterized by robust growth potential and strategic expansion initiatives. Over recent years, the company has aggressively pursued both organic growth and acquisitions to strengthen its product offerings and market reach. This includes partnerships with renowned companies to develop cutting-edge treatments and technologies. The organization’s emphasis on global healthcare trends, along with its commitment to enhancing patient well-being through innovative solutions, underscores its long-term vision. Investors can view Fosun Pharma as a vital player in addressing healthcare needs, especially in the wake of increasing global demand for health solutions, thus making it an attractive proposition in the pharmaceutical industry.

Intrinsic Value
38.86 CNY
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Shanghai Fosun Pharmaceutical Group Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
3.5B CNY

Based on the financial report for Jun 30, 2024, Shanghai Fosun Pharmaceutical Group Co Ltd's Cash from Operating Activities amounts to 3.5B CNY.

What is Shanghai Fosun Pharmaceutical Group Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
12%

Over the last year, the Cash from Operating Activities growth was -17%. The average annual Cash from Operating Activities growth rates for Shanghai Fosun Pharmaceutical Group Co Ltd have been 8% over the past three years , 2% over the past five years , and 12% over the past ten years .

Back to Top